VOR (vorbio.com) Business Value to Revenue

Vor Biopharma (VOR) - corporate logo

Risks for Vor Biopharma Inc. (VOR) are linked to stringent FDA oversight and the lack of a broad customer base. However, the GURU.Markets platform reflects the EV-to-revenue ratio, where the current level is 0.00, which helps identify support. Growth potential is based on scaling gene editing and creating unique cell protection for leukemia therapy.

Vor Biopharma Inc. (VOR) - EV/Sales Multiple from 11/23/2025 to 11/20/2026

VOR (Vor Biopharma): analytical breakdowns and indicator data

- current price and projected stock value:
- business market valuation indicators:
Fundamental company valuation:Vor Biopharma Inc. VOR
Core merchandise of vorbio.com

This metric combines market capitalization and net debt, benchmarking them against sales volume to determine the enterprise value by excluding the impact of leverage on the valuation. For Vor Biopharma Inc. (VOR), this calculation highlights the speculative nature of its valuation against a backdrop of minimal revenue. A narrow specialization in leukemia treatment amplifies the volatility of the enterprise value-to-revenue ratio. This chart reflects market expectations regarding binary pipeline risks.